ID   RAC1_HUMAN              Reviewed;         192 AA.
AC   P63000; O95501; P15154; Q3Y4D3; Q5JAA8; Q9BTB4;
DT   31-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   31-AUG-2004, sequence version 1.
DT   05-FEB-2025, entry version 221.
DE   RecName: Full=Ras-related C3 botulinum toxin substrate 1 {ECO:0000305};
DE            EC=3.6.5.2 {ECO:0000269|PubMed:21565175};
DE   AltName: Full=Cell migration-inducing gene 5 protein;
DE   AltName: Full=Ras-like protein TC25;
DE   AltName: Full=p21-Rac1;
DE   Flags: Precursor;
GN   Name=RAC1 {ECO:0000312|HGNC:HGNC:9801}; Synonyms=TC25; ORFNames=MIG5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=2674130; DOI=10.1016/s0021-9258(19)84716-6;
RA   Didsbury J., Weber R.F., Bokoch G.M., Evans T., Snyderman R.;
RT   "Rac, a novel ras-related family of proteins that are botulinum toxin
RT   substrates.";
RL   J. Biol. Chem. 264:16378-16382(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=2108320; DOI=10.1128/mcb.10.4.1793-1798.1990;
RA   Drivas G.T., Shih A., Coutavas E., Rush M.G., D'Eustachio P.;
RT   "Characterization of four novel ras-like genes expressed in a human
RT   teratocarcinoma cell line.";
RL   Mol. Cell. Biol. 10:1793-1798(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS A AND B).
RX   PubMed=11062023; DOI=10.1006/bbrc.2000.3743;
RA   Matos P., Skaug J., Marques B., Beck S., Verissimo F., Gespach C.,
RA   Boavida M.G., Scherer S.W., Jordan P.;
RT   "Small GTPase Rac1: structure, localization, and expression of the human
RT   gene.";
RL   Biochem. Biophys. Res. Commun. 277:741-751(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B).
RC   TISSUE=Colon, and Skin;
RX   PubMed=10597294; DOI=10.1038/sj.onc.1203233;
RA   Jordan P., Brazao R., Boavida M.G., Gespach C., Chastre E.;
RT   "Cloning of a novel human Rac1b splice variant with increased expression in
RT   colorectal tumors.";
RL   Oncogene 18:6835-6839(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RA   Schnelzer A., Knaus U., Prechtel D., Dehne K., Harbeck N., Gerhard M.,
RA   Schmitt M., Lengyel E.;
RT   "Mutations and altered expression of Rac1 in human breast cancer
RT   -- characterization of a new Rac1 isoform, Rac1ins.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RA   Kim J.W.;
RT   "Identification of a human migration-inducing gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A), AND VARIANT ILE-135.
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Pancreas, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   SUBCELLULAR LOCATION, AND ISOPRENYLATION AT CYS-189.
RX   PubMed=1903399; DOI=10.1016/s0021-9258(18)92889-9;
RA   Kinsella B.T., Erdman R.A., Maltese W.A.;
RT   "Carboxyl-terminal isoprenylation of ras-related GTP-binding proteins
RT   encoded by rac1, rac2, and ralA.";
RL   J. Biol. Chem. 266:9786-9794(1991).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1643658; DOI=10.1016/0092-8674(92)90164-8;
RA   Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., Hall A.;
RT   "The small GTP-binding protein rac regulates growth factor-induced membrane
RT   ruffling.";
RL   Cell 70:401-410(1992).
RN   [14]
RP   GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION).
RX   PubMed=7777059; DOI=10.1038/375500a0;
RA   Just I., Selzer J., Wilm M., von Eichel-Streiber C., Mann M., Aktories K.;
RT   "Glucosylation of Rho proteins by Clostridium difficile toxin B.";
RL   Nature 375:500-503(1995).
RN   [15]
RP   GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION).
RX   PubMed=7775453; DOI=10.1074/jbc.270.23.13932;
RA   Just I., Wilm M., Selzer J., Rex G., von Eichel-Streiber C., Mann M.,
RA   Aktories K.;
RT   "The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho
RT   proteins.";
RL   J. Biol. Chem. 270:13932-13936(1995).
RN   [16]
RP   INTERACTION WITH RALBP1.
RX   PubMed=7673236; DOI=10.1074/jbc.270.38.22473;
RA   Jullien-Flores V., Dorseuil O., Romero F., Letourneur F., Saragosti S.,
RA   Berger R., Tavitian A., Gacon G., Camonis J.H.;
RT   "Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac
RT   GTPase-activating protein activity.";
RL   J. Biol. Chem. 270:22473-22477(1995).
RN   [17]
RP   GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION).
RX   PubMed=8626575; DOI=10.1074/jbc.271.17.10149;
RA   Just I., Selzer J., Hofmann F., Green G.A., Aktories K.;
RT   "Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed
RT   glucosylation.";
RL   J. Biol. Chem. 271:10149-10153(1996).
RN   [18]
RP   GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION).
RX   PubMed=8810274; DOI=10.1074/jbc.271.41.25173;
RA   Selzer J., Hofmann F., Rex G., Wilm M., Mann M., Just I., Aktories K.;
RT   "Clostridium novyi alpha-toxin-catalyzed incorporation of GlcNAc into Rho
RT   subfamily proteins.";
RL   J. Biol. Chem. 271:25173-25177(1996).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH PKN2.
RX   PubMed=9121475; DOI=10.1128/mcb.17.4.2247;
RA   Vincent S., Settleman J.;
RT   "The PRK2 kinase is a potential effector target of both Rho and Rac GTPases
RT   and regulates actin cytoskeletal organization.";
RL   Mol. Cell. Biol. 17:2247-2256(1997).
RN   [20]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=9857026; DOI=10.1074/jbc.273.52.34954;
RA   Ren Y., Li R., Zheng Y., Busch H.;
RT   "Cloning and characterization of GEF-H1, a microtubule-associated guanine
RT   nucleotide exchange factor for Rac and Rho GTPases.";
RL   J. Biol. Chem. 273:34954-34960(1998).
RN   [21]
RP   INTERACTION WITH DOCK2.
RX   PubMed=10559471; DOI=10.1016/s0167-4889(99)00133-0;
RA   Nishihara H., Kobayashi S., Hashimoto Y., Ohba F., Mochizuki N., Kurata T.,
RA   Nagashima K., Matsuda M.;
RT   "Non-adherent cell-specific expression of DOCK2, a member of the human CDM-
RT   family proteins.";
RL   Biochim. Biophys. Acta 1452:179-187(1999).
RN   [22]
RP   INTERACTION WITH PARD6A, AND MUTAGENESIS OF GLN-61.
RX   PubMed=10954424; DOI=10.1242/jcs.113.18.3267;
RA   Johansson A.-S., Driessens M., Aspenstroem P.;
RT   "The mammalian homologue of the Caenorhabditis elegans polarity protein
RT   PAR-6 is a binding partner for the Rho GTPases Cdc42 and Rac1.";
RL   J. Cell Sci. 113:3267-3275(2000).
RN   [23]
RP   INTERACTION WITH BAIAP2.
RX   PubMed=11130076; DOI=10.1038/35047107;
RA   Miki H., Yamaguchi H., Suetsugu S., Takenawa T.;
RT   "IRSp53 is an essential intermediate between Rac and WAVE in the regulation
RT   of membrane ruffling.";
RL   Nature 408:732-735(2000).
RN   [24]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=11035813; DOI=10.1073/pnas.220421797;
RA   Vikis H.G., Li W., He Z., Guan K.-L.;
RT   "The semaphorin receptor plexin-B1 specifically interacts with active Rac
RT   in a ligand-dependent manner.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12457-12462(2000).
RN   [25]
RP   PHOSPHORYLATION AT SER-71, AND MUTAGENESIS OF SER-71.
RX   PubMed=10617634; DOI=10.1074/jbc.275.1.423;
RA   Kwon T., Kwon D.Y., Chun J., Kim J.H., Kang S.S.;
RT   "Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at
RT   serine 71 of Rac1.";
RL   J. Biol. Chem. 275:423-428(2000).
RN   [26]
RP   INTERACTION WITH PARD6A; PARD6B AND PARD6G; PRKCI AND PRKCZ, AND
RP   MUTAGENESIS OF GLY-12 AND THR-17.
RX   PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x;
RA   Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.;
RT   "Human homologues of the Caenorhabditis elegans cell polarity protein PAR6
RT   as an adaptor that links the small GTPases Rac and Cdc42 to atypical
RT   protein kinase C.";
RL   Genes Cells 6:107-119(2001).
RN   [27]
RP   ACTIVATION BY PREX1.
RX   PubMed=11955434; DOI=10.1016/s0092-8674(02)00663-3;
RA   Welch H.C.E., Coadwell W.J., Ellson C.D., Ferguson G.J., Andrews S.R.,
RA   Erdjument-Bromage H., Tempst P., Hawkins P.T., Stephens L.R.;
RT   "P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide
RT   exchange factor for Rac.";
RL   Cell 108:809-821(2002).
RN   [28]
RP   INTERACTION WITH ITGB1BP1.
RX   PubMed=11807099; DOI=10.1083/jcb.200108030;
RA   Degani S., Balzac F., Brancaccio M., Guazzone S., Retta S.F., Silengo L.,
RA   Eva A., Tarone G.;
RT   "The integrin cytoplasmic domain-associated protein ICAP-1 binds and
RT   regulates Rho family GTPases during cell spreading.";
RL   J. Cell Biol. 156:377-387(2002).
RN   [29]
RP   SUBUNIT OF A COMPLEX CONTAINING ELMO1 AND DOCK1.
RX   PubMed=12134158; DOI=10.1038/ncb824;
RA   Brugnera E., Haney L., Grimsley C., Lu M., Walk S.F.,
RA   Tosello-Trampont A.-C., Macara I.G., Madhani H., Fink G.R.,
RA   Ravichandran K.S.;
RT   "Unconventional Rac-GEF activity is mediated through the Dock180-ELMO
RT   complex.";
RL   Nat. Cell Biol. 4:574-582(2002).
RN   [30]
RP   INTERACTION WITH RAP1GDS1, SUBCELLULAR LOCATION, AND POLYBASIC REGION.
RX   PubMed=12551911; DOI=10.1074/jbc.m211286200;
RA   Lanning C.C., Ruiz-Velasco R., Williams C.L.;
RT   "Novel mechanism of the co-regulation of nuclear transport of SmgGDS and
RT   Rac1.";
RL   J. Biol. Chem. 278:12495-12506(2003).
RN   [31]
RP   INTERACTION WITH NOXA1.
RX   PubMed=12716910; DOI=10.1074/jbc.m212856200;
RA   Takeya R., Ueno N., Kami K., Taura M., Kohjima M., Izaki T., Nunoi H.,
RA   Sumimoto H.;
RT   "Novel human homologues of p47phox and p67phox participate in activation of
RT   superoxide-producing NADPH oxidases.";
RL   J. Biol. Chem. 278:25234-25246(2003).
RN   [32]
RP   FUNCTION.
RX   PubMed=12695502; DOI=10.1083/jcb.200211002;
RA   Zhang H., Webb D.J., Asmussen H., Horwitz A.F.;
RT   "Synapse formation is regulated by the signaling adaptor GIT1.";
RL   J. Cell Biol. 161:131-142(2003).
RN   [33]
RP   INTERACTION WITH USP6.
RX   PubMed=12612085; DOI=10.1128/mcb.23.6.2151-2161.2003;
RA   Masuda-Robens J.M., Kutney S.N., Qi H., Chou M.M.;
RT   "The TRE17 oncogene encodes a component of a novel effector pathway for Rho
RT   GTPases Cdc42 and Rac1 and stimulates actin remodeling.";
RL   Mol. Cell. Biol. 23:2151-2161(2003).
RN   [34]
RP   RETRACTED PAPER.
RX   PubMed=15169762; DOI=10.1074/jbc.m401878200;
RA   Li W., Guan K.L.;
RT   "The Down syndrome cell adhesion molecule (DSCAM) interacts with and
RT   activates Pak.";
RL   J. Biol. Chem. 279:32824-32831(2004).
RN   [35]
RP   RETRACTION NOTICE OF PUBMED:15169762.
RX   PubMed=26048998; DOI=10.1074/jbc.a115.401878;
RA   Li W., Guan K.L.;
RT   "The Down syndrome cell adhesion molecule (DSCAM) interacts with and
RT   activates Pak.";
RL   J. Biol. Chem. 290:14797-14797(2015).
RN   [36]
RP   INTERACTION WITH S100A8 AND CALPROTECTIN.
RX   PubMed=15642721; DOI=10.1096/fj.04-2377fje;
RA   Kerkhoff C., Nacken W., Benedyk M., Dagher M.C., Sopalla C., Doussiere J.;
RT   "The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase
RT   activation by interaction with p67phox and Rac-2.";
RL   FASEB J. 19:467-469(2005).
RN   [37]
RP   INTERACTION WITH DOCK4.
RX   PubMed=16464467; DOI=10.1016/j.jmb.2006.01.017;
RA   Yan D., Li F., Hall M.L., Sage C., Hu W.H., Giallourakis C., Upadhyay G.,
RA   Ouyang X.M., Du L.L., Bethea J.R., Chen Z.Y., Yajnik V., Liu X.Z.;
RT   "An isoform of GTPase regulator DOCK4 localizes to the stereocilia in the
RT   inner ear and binds to harmonin (USH1C).";
RL   J. Mol. Biol. 357:755-764(2006).
RN   [38]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [39]
RP   INTERACTION WITH DOCK7.
RX   PubMed=16982419; DOI=10.1016/j.neuron.2006.07.020;
RA   Watabe-Uchida M., John K.A., Janas J.A., Newey S.E., Van Aelst L.;
RT   "The Rac activator DOCK7 regulates neuronal polarity through local
RT   phosphorylation of stathmin/Op18.";
RL   Neuron 51:727-739(2006).
RN   [40]
RP   INTERACTION WITH DEF6, AND DOMAIN.
RX   PubMed=17121847; DOI=10.1074/jbc.m605153200;
RA   Oka T., Ihara S., Fukui Y.;
RT   "Cooperation of DEF6 with activated Rac in regulating cell morphology.";
RL   J. Biol. Chem. 282:2011-2018(2007).
RN   [41]
RP   INTERACTION WITH BAIAP2L1.
RX   PubMed=17430976; DOI=10.1242/jcs.001776;
RA   Millard T.H., Dawson J., Machesky L.M.;
RT   "Characterisation of IRTKS, a novel IRSp53/MIM family actin regulator with
RT   distinct filament bundling properties.";
RL   J. Cell Sci. 120:1663-1672(2007).
RN   [42]
RP   INTERACTION WITH SPATA13.
RX   PubMed=17145773; DOI=10.1128/mcb.01608-06;
RA   Hamann M.J., Lubking C.M., Luchini D.N., Billadeau D.D.;
RT   "Asef2 functions as a Cdc42 exchange factor and is stimulated by the
RT   release of an autoinhibitory module from a concealed C-terminal activation
RT   element.";
RL   Mol. Cell. Biol. 27:1380-1393(2007).
RN   [43]
RP   INTERACTION WITH RAPH1, AND MUTAGENESIS OF GLN-61.
RX   PubMed=18499456; DOI=10.1016/j.cub.2008.04.050;
RA   Quinn C.C., Pfeil D.S., Wadsworth W.G.;
RT   "CED-10/Rac1 mediates axon guidance by regulating the asymmetric
RT   distribution of MIG-10/lamellipodin.";
RL   Curr. Biol. 18:808-813(2008).
RN   [44]
RP   UBIQUITINATION AT LYS-147.
RX   PubMed=18093184; DOI=10.1111/j.1742-4658.2007.06209.x;
RA   Visvikis O., Lores P., Boyer L., Chardin P., Lemichez E., Gacon G.;
RT   "Activated Rac1, but not the tumorigenic variant Rac1b, is ubiquitinated on
RT   Lys 147 through a JNK-regulated process.";
RL   FEBS J. 275:386-396(2008).
RN   [45]
RP   FUNCTION, AND MUTAGENESIS OF GLY-12 AND THR-17.
RX   PubMed=19029984; DOI=10.1038/nm.1879;
RA   Shibata S., Nagase M., Yoshida S., Kawarazaki W., Kurihara H., Tanaka H.,
RA   Miyoshi J., Takai Y., Fujita T.;
RT   "Modification of mineralocorticoid receptor function by Rac1 GTPase:
RT   implication in proteinuric kidney disease.";
RL   Nat. Med. 14:1370-1376(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71 (ISOFORM B), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [47]
RP   GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION).
RX   PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006;
RA   Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.;
RT   "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation
RT   catalysed by Clostridium sordellii lethal toxin.";
RL   FEBS Lett. 583:3133-3139(2009).
RN   [48]
RP   FUNCTION.
RX   PubMed=19934221; DOI=10.1242/jcs.053728;
RA   Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.;
RT   "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin
RT   dynamics and thereby regulate cell migration.";
RL   J. Cell Sci. 122:4535-4546(2009).
RN   [49]
RP   INTERACTION WITH MTSS2.
RX   PubMed=20875796; DOI=10.1016/j.bbrc.2010.09.087;
RA   Zheng D., Niu S., Yu D., Zhan X.H., Zeng X., Cui B., Chen Y., Yoon J.,
RA   Martin S.S., Lu X., Zhan X.;
RT   "Abba promotes PDGF-mediated membrane ruffling through activation of the
RT   small GTPase Rac1.";
RL   Biochem. Biophys. Res. Commun. 401:527-532(2010).
RN   [50]
RP   INTERACTION WITH UNKL.
RX   PubMed=20148946; DOI=10.1111/j.1742-4658.2010.07575.x;
RA   Lores P., Visvikis O., Luna R., Lemichez E., Gacon G.;
RT   "The SWI/SNF protein BAF60b is ubiquitinated through a signalling process
RT   involving Rac GTPase and the RING finger protein Unkempt.";
RL   FEBS J. 277:1453-1464(2010).
RN   [51]
RP   FUNCTION, AND INTERACTION WITH ITGB4.
RX   PubMed=19403692; DOI=10.1091/mbc.e09-01-0051;
RA   Hamill K.J., Hopkinson S.B., DeBiase P., Jones J.C.;
RT   "BPAG1e maintains keratinocyte polarity through beta4 integrin-mediated
RT   modulation of Rac1 and cofilin activities.";
RL   Mol. Biol. Cell 20:2954-2962(2009).
RN   [52]
RP   AMPYLATION AT TYR-32 (MICROBIAL INFECTION), IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF TYR-32.
RX   PubMed=19362538; DOI=10.1016/j.molcel.2009.03.008;
RA   Worby C.A., Mattoo S., Kruger R.P., Corbeil L.B., Koller A., Mendez J.C.,
RA   Zekarias B., Lazar C., Dixon J.E.;
RT   "The fic domain: regulation of cell signaling by adenylylation.";
RL   Mol. Cell 34:93-103(2009).
RN   [53]
RP   AMPYLATION AT THR-35 (MICROBIAL INFECTION), IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF THR-35.
RX   PubMed=19039103; DOI=10.1126/science.1166382;
RA   Yarbrough M.L., Li Y., Kinch L.N., Grishin N.V., Ball H.L., Orth K.;
RT   "AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and
RT   downstream signaling.";
RL   Science 323:269-272(2009).
RN   [54]
RP   INTERACTION WITH TBC1D2.
RX   PubMed=20116244; DOI=10.1016/j.cub.2009.12.053;
RA   Frasa M.A., Maximiano F.C., Smolarczyk K., Francis R.E., Betson M.E.,
RA   Lozano E., Goldenring J., Seabra M.C., Rak A., Ahmadian M.R., Braga V.M.;
RT   "Armus is a Rac1 effector that inactivates Rab7 and regulates E-cadherin
RT   degradation.";
RL   Curr. Biol. 20:198-208(2010).
RN   [55]
RP   INTERACTION WITH PAK2; SH3RF1 AND SH3RF3.
RX   PubMed=20696164; DOI=10.1016/j.febslet.2010.07.060;
RA   Kaerkkaeinen S., van der Linden M., Renkema G.H.;
RT   "POSH2 is a RING finger E3 ligase with Rac1 binding activity through a
RT   partial CRIB domain.";
RL   FEBS Lett. 584:3867-3872(2010).
RN   [56]
RP   FUNCTION.
RX   PubMed=20696765; DOI=10.1074/jbc.m110.120451;
RA   Li X., Lee A.Y.;
RT   "Semaphorin 5A and plexin-B3 inhibit human glioma cell motility through
RT   RhoGDIalpha-mediated inactivation of Rac1 GTPase.";
RL   J. Biol. Chem. 285:32436-32445(2010).
RN   [57]
RP   FUNCTION, INTERACTION WITH PPP5C, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   THR-17; GLY-30; THR-35 AND GLN-61.
RX   PubMed=19948726; DOI=10.1074/jbc.m109.088427;
RA   Chatterjee A., Wang L., Armstrong D.L., Rossie S.;
RT   "Activated Rac1 GTPase translocates protein phosphatase 5 to the cell
RT   membrane and stimulates phosphatase activity in vitro.";
RL   J. Biol. Chem. 285:3872-3882(2010).
RN   [58]
RP   INTERACTION WITH RAP1GDS1.
RX   PubMed=20709748; DOI=10.1074/jbc.m110.129916;
RA   Berg T.J., Gastonguay A.J., Lorimer E.L., Kuhnmuench J.R., Li R.,
RA   Fields A.P., Williams C.L.;
RT   "Splice variants of SmgGDS control small GTPase prenylation and membrane
RT   localization.";
RL   J. Biol. Chem. 285:35255-35266(2010).
RN   [59]
RP   INTERACTION WITH ARHGEF16.
RX   PubMed=20679435; DOI=10.1083/jcb.201005141;
RA   Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S.,
RA   Negishi M., Katoh H.;
RT   "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent
RT   mechanism.";
RL   J. Cell Biol. 190:461-477(2010).
RN   [60]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [61]
RP   ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=21565175; DOI=10.1016/j.bbrc.2011.04.116;
RA   Naji L., Pacholsky D., Aspenstrom P.;
RT   "ARHGAP30 is a Wrch-1-interacting protein involved in actin dynamics and
RT   cell adhesion.";
RL   Biochem. Biophys. Res. Commun. 409:96-102(2011).
RN   [62]
RP   UBIQUITINATION.
RX   PubMed=22036506; DOI=10.1016/j.devcel.2011.08.015;
RA   Torrino S., Visvikis O., Doye A., Boyer L., Stefani C., Munro P.,
RA   Bertoglio J., Gacon G., Mettouchi A., Lemichez E.;
RT   "The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active
RT   Rac1.";
RL   Dev. Cell 21:959-965(2011).
RN   [63]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PACSIN2.
RX   PubMed=21693584; DOI=10.1242/jcs.080630;
RA   de Kreuk B.J., Nethe M., Fernandez-Borja M., Anthony E.C., Hensbergen P.J.,
RA   Deelder A.M., Plomann M., Hordijk P.L.;
RT   "The F-BAR domain protein PACSIN2 associates with Rac1 and regulates cell
RT   spreading and migration.";
RL   J. Cell Sci. 124:2375-2388(2011).
RN   [64]
RP   INTERACTION WITH PKN2.
RX   PubMed=20974804; DOI=10.1128/mcb.01001-10;
RA   Wallace S.W., Magalhaes A., Hall A.;
RT   "The Rho target PRK2 regulates apical junction formation in human bronchial
RT   epithelial cells.";
RL   Mol. Cell. Biol. 31:81-91(2011).
RN   [65]
RP   FUNCTION, AND INTERACTION WITH DSG3.
RX   PubMed=22796473; DOI=10.1016/j.yexcr.2012.07.002;
RA   Tsang S.M., Brown L., Gadmor H., Gammon L., Fortune F., Wheeler A., Wan H.;
RT   "Desmoglein 3 acting as an upstream regulator of Rho GTPases, Rac-1/Cdc42
RT   in the regulation of actin organisation and dynamics.";
RL   Exp. Cell Res. 318:2269-2283(2012).
RN   [66]
RP   FUNCTION, INTERACTION WITH CD151 AND INTEGRIN BETA1/ITGB1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=22843693; DOI=10.1074/jbc.m111.314443;
RA   Hong I.K., Jeoung D.I., Ha K.S., Kim Y.M., Lee H.;
RT   "Tetraspanin CD151 stimulates adhesion-dependent activation of Ras, Rac,
RT   and Cdc42 by facilitating molecular association between beta1 integrins and
RT   small GTPases.";
RL   J. Biol. Chem. 287:32027-32039(2012).
RN   [67]
RP   INTERACTION WITH FARP1.
RX   PubMed=23209303; DOI=10.1083/jcb.201205041;
RA   Cheadle L., Biederer T.;
RT   "The novel synaptogenic protein Farp1 links postsynaptic cytoskeletal
RT   dynamics and transsynaptic organization.";
RL   J. Cell Biol. 199:985-1001(2012).
RN   [68]
RP   FUNCTION, MUTAGENESIS OF SER-71 AND LYS-166, AND UBIQUITINATION AT LYS-166.
RX   PubMed=23512198; DOI=10.1096/fj.12-223099;
RA   Zhao J., Mialki R.K., Wei J., Coon T.A., Zou C., Chen B.B.,
RA   Mallampalli R.K., Zhao Y.;
RT   "SCF E3 ligase F-box protein complex SCF(FBXL19) regulates cell migration
RT   by mediating Rac1 ubiquitination and degradation.";
RL   FASEB J. 27:2611-2619(2013).
RN   [69]
RP   INTERACTION WITH ARHGDIA.
RX   PubMed=23434736; DOI=10.1136/jmedgenet-2012-101442;
RA   Gupta I.R., Baldwin C., Auguste D., Ha K.C., El Andalousi J.,
RA   Fahiminiya S., Bitzan M., Bernard C., Akbari M.R., Narod S.A.,
RA   Rosenblatt D.S., Majewski J., Takano T.;
RT   "ARHGDIA: a novel gene implicated in nephrotic syndrome.";
RL   J. Med. Genet. 50:330-338(2013).
RN   [70]
RP   FUNCTION.
RX   PubMed=23633677; DOI=10.1126/scisignal.2003627;
RA   Borroni E.M., Cancellieri C., Vacchini A., Benureau Y., Lagane B.,
RA   Bachelerie F., Arenzana-Seisdedos F., Mizuno K., Mantovani A., Bonecchi R.,
RA   Locati M.;
RT   "Beta-arrestin-dependent activation of the cofilin pathway is required for
RT   the scavenging activity of the atypical chemokine receptor D6.";
RL   Sci. Signal. 6:RA30-RA30(2013).
RN   [71]
RP   GLYCOSYLATION AT TYR-32 (MICROBIAL INFECTION).
RX   PubMed=24141704; DOI=10.1038/nsmb.2688;
RA   Jank T., Bogdanovic X., Wirth C., Haaf E., Spoerner M., Boehmer K.E.,
RA   Steinemann M., Orth J.H., Kalbitzer H.R., Warscheid B., Hunte C.,
RA   Aktories K.;
RT   "A bacterial toxin catalyzing tyrosine glycosylation of Rho and deamidation
RT   of Gq and Gi proteins.";
RL   Nat. Struct. Mol. Biol. 20:1273-1280(2013).
RN   [72]
RP   INTERACTION WITH FARP2.
RX   PubMed=23375260; DOI=10.1016/j.str.2013.01.001;
RA   He X., Kuo Y.C., Rosche T.J., Zhang X.;
RT   "Structural basis for autoinhibition of the guanine nucleotide exchange
RT   factor FARP2.";
RL   Structure 21:355-364(2013).
RN   [73]
RP   GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION).
RX   PubMed=24905543; DOI=10.1111/cmi.12321;
RA   Genth H., Pauillac S., Schelle I., Bouvet P., Bouchier C.,
RA   Varela-Chavez C., Just I., Popoff M.R.;
RT   "Haemorrhagic toxin and lethal toxin from Clostridium sordellii strain
RT   vpi9048: molecular characterization and comparative analysis of substrate
RT   specificity of the large clostridial glucosylating toxins.";
RL   Cell. Microbiol. 16:1706-1721(2014).
RN   [74]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [75]
RP   FUNCTION, INVOLVEMENT IN MRD48, VARIANTS MRD48 TYR-18; SER-39; LEU-51;
RP   MET-51; ASP-64; LEU-73 AND TYR-157, AND CHARACTERIZATION OF VARIANTS MRD48
RP   TYR-18; SER-39; MET-51; ASP-64; LEU-73 AND TYR-157.
RX   PubMed=28886345; DOI=10.1016/j.ajhg.2017.08.007;
RG   Deciphering Developmental Disorders Study;
RA   Reijnders M.R.F., Ansor N.M., Kousi M., Yue W.W., Tan P.L., Clarkson K.,
RA   Clayton-Smith J., Corning K., Jones J.R., Lam W.W.K., Mancini G.M.S.,
RA   Marcelis C., Mohammed S., Pfundt R., Roifman M., Cohn R., Chitayat D.,
RA   Millard T.H., Katsanis N., Brunner H.G., Banka S.;
RT   "RAC1 Missense Mutations in Developmental Disorders with Diverse
RT   Phenotypes.";
RL   Am. J. Hum. Genet. 101:466-477(2017).
RN   [76]
RP   PALMITOYLATION AT LYS-183 AND LYS-184 (MICROBIAL INFECTION), SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF GLY-12; 183-LYS--LYS-188; LYS-183; LYS-184;
RP   185-ARG--ARG-187; LYS-186 AND LYS-188.
RX   PubMed=29074776; DOI=10.1126/science.aam8659;
RA   Zhou Y., Huang C., Yin L., Wan M., Wang X., Li L., Liu Y., Wang Z., Fu P.,
RA   Zhang N., Chen S., Liu X., Shao F., Zhu Y.;
RT   "Nepsilon-fatty acylation of Rho GTPases by a MARTX toxin effector.";
RL   Science 358:528-531(2017).
RN   [77]
RP   INTERACTION WITH CYRIB, AND MUTAGENESIS OF GLY-12; THR-17 AND GLN-61.
RX   PubMed=30250061; DOI=10.1038/s41556-018-0198-9;
RA   Fort L., Batista J.M., Thomason P.A., Spence H.J., Whitelaw J.A.,
RA   Tweedy L., Greaves J., Martin K.J., Anderson K.I., Brown P., Lilla S.,
RA   Neilson M.P., Tafelmeyer P., Zanivan S., Ismail S., Bryant D.M.,
RA   Tomkinson N.C.O., Chamberlain L.H., Mastick G.S., Insall R.H.,
RA   Machesky L.M.;
RT   "Fam49/CYRI interacts with Rac1 and locally suppresses protrusions.";
RL   Nat. Cell Biol. 20:1159-1171(2018).
RN   [78]
RP   INTERACTION WITH CYRIB.
RX   PubMed=31285585; DOI=10.1038/s41564-019-0484-8;
RA   Yuki K.E., Marei H., Fiskin E., Eva M.M., Gopal A.A.,
RA   Schwartzentruber J.A., Majewski J., Cellier M., Mandl J.N., Vidal S.M.,
RA   Malo D., Dikic I.;
RT   "CYRI/FAM49B negatively regulates RAC1-driven cytoskeletal remodelling and
RT   protects against bacterial infection.";
RL   Nat. Microbiol. 4:1516-1531(2019).
RN   [79]
RP   INTERACTION WITH GARRE1, AND MUTAGENESIS OF GLY-12.
RX   PubMed=31871319; DOI=10.1038/s41556-019-0438-7;
RA   Bagci H., Sriskandarajah N., Robert A., Boulais J., Elkholi I.E., Tran V.,
RA   Lin Z.Y., Thibault M.P., Dube N., Faubert D., Hipfner D.R., Gingras A.C.,
RA   Cote J.F.;
RT   "Mapping the proximity interaction network of the Rho-family GTPases
RT   reveals signalling pathways and regulatory mechanisms.";
RL   Nat. Cell Biol. 22:120-134(2020).
RN   [80]
RP   INTERACTION WITH TNFAIP8L2.
RX   PubMed=32460619; DOI=10.1080/15548627.2020.1761748;
RA   Li W., Li Y., Guan Y., Du Y., Zhao M., Chen X., Zhu F., Guo C., Jia Y.,
RA   Li Y., Wang X., Wang X., Shi Y., Wang Q., Li Y., Zhang L.;
RT   "TNFAIP8L2/TIPE2 impairs autolysosome reformation via modulating the RAC1-
RT   MTORC1 axis.";
RL   Autophagy 17:1410-1425(2021).
RN   [81]
RP   INTERACTION WITH ARHGAP36.
RX   PubMed=35986704; DOI=10.1111/bjd.21842;
RA   Liu Y., Banka S., Huang Y., Hardman-Smart J., Pye D., Torrelo A.,
RA   Beaman G.M., Kazanietz M.G., Baker M.J., Ferrazzano C., Shi C., Orozco G.,
RA   Eyre S., van Geel M., Bygum A., Fischer J., Miedzybrodzka Z., Abuzahra F.,
RA   Ruebben A., Cuvertino S., Ellingford J.M., Smith M.J., Evans D.G.,
RA   Weppner-Parren L.J.M.T., van Steensel M.A.M., Chaudhary I.H., Mangham D.C.,
RA   Lear J.T., Paus R., Frank J., Newman W.G., Zhang X.;
RT   "Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol
RT   basal cell carcinoma susceptibility syndrome.";
RL   Br. J. Dermatol. 187:948-961(2022).
RN   [82]
RP   X-RAY CRYSTALLOGRAPHY (1.38 ANGSTROMS) OF 1-184 IN COMPLEX WITH GTP ANALOG.
RX   PubMed=9033596; DOI=10.1038/nsb0297-147;
RA   Hirshberg M., Stockley R.W., Dodson G., Webb M.R.;
RT   "The crystal structure of human rac1, a member of the rho-family complexed
RT   with a GTP analogue.";
RL   Nat. Struct. Biol. 4:147-152(1997).
RN   [83]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF MUTANT LEU-61 IN COMPLEX WITH GTP
RP   AND NCF2.
RX   PubMed=11090627; DOI=10.1016/s1097-2765(05)00091-2;
RA   Lapouge K., Smith S.J., Walker P.A., Gamblin S.J., Smerdon S.J.,
RA   Rittinger K.;
RT   "Structure of the TPR domain of p67phox in complex with Rac.GTP.";
RL   Mol. Cell 6:899-907(2000).
RN   [84]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-177 IN COMPLEX WITH TIAM1.
RX   PubMed=11130063; DOI=10.1038/35047014;
RA   Worthylake D.K., Rossman K.L., Sondek J.;
RT   "Crystal structure of Rac1 in complex with the guanine nucleotide exchange
RT   region of Tiam1.";
RL   Nature 408:682-688(2000).
RN   [85]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-184 IN COMPLEX WITH SALMONELLA
RP   SPTP.
RX   PubMed=11163217; DOI=10.1016/s1097-2765(00)00141-6;
RA   Stebbins C.E., Galan J.E.;
RT   "Modulation of host signaling by a bacterial mimic: structure of the
RT   Salmonella effector SptP bound to Rac1.";
RL   Mol. Cell 6:1449-1460(2000).
RN   [86]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-176 IN COMPLEX WITH GTP ANALOG
RP   AND P.AERUGINOSA EXOS.
RX   PubMed=11135665; DOI=10.1038/83007;
RA   Wuertele M., Wolf E., Pederson K.J., Buchwald G., Ahmadian M.R.,
RA   Barbieri J.T., Wittinghofer A.;
RT   "How the Pseudomonas aeruginosa ExoS toxin downregulates Rac.";
RL   Nat. Struct. Biol. 8:23-26(2001).
RN   [87]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH ARHGDIA.
RX   PubMed=11513578; DOI=10.1021/bi010288k;
RA   Grizot S., Faure J., Fieschi F., Vignais P.V., Dagher M.-C.,
RA   Pebay-Peyroula E.;
RT   "Crystal structure of the Rac1-RhoGDI complex involved in NADPH oxidase
RT   activation.";
RL   Biochemistry 40:10007-10013(2001).
RN   [88]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH GTP ANALOG AND
RP   ARFIP2.
RX   PubMed=11346801; DOI=10.1038/35075620;
RA   Tarricone C., Xiao B., Justin N., Walker P.A., Rittinger K., Gamblin S.J.,
RA   Smerdon S.J.;
RT   "The structural basis of Arfaptin-mediated cross-talk between Rac and Arf
RT   signalling pathways.";
RL   Nature 411:215-219(2001).
RN   [89]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF ISOFORM B, AND FUNCTION (ISOFORM
RP   B).
RX   PubMed=14625275; DOI=10.1074/jbc.m310281200;
RA   Fiegen D., Haeusler L.C., Blumenstein L., Herbrand U., Dvorsky R.,
RA   Vetter I.R., Ahmadian M.R.;
RT   "Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase.";
RL   J. Biol. Chem. 279:4743-4749(2004).
RN   [90]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-184 IN COMPLEX WITH
RP   Y.PSEUDOTUBERCULOSIS YPKA.
RX   PubMed=16959567; DOI=10.1016/j.cell.2006.06.056;
RA   Prehna G., Ivanov M.I., Bliska J.B., Stebbins C.E.;
RT   "Yersinia virulence depends on mimicry of host Rho-family nucleotide
RT   dissociation inhibitors.";
RL   Cell 126:869-880(2006).
RN   [91]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-177 IN COMPLEX WITH GTP ANALOG
RP   AND PLCB2, AND MUTAGENESIS OF PHE-37; TRP-56; LEU-67 AND LEU-70.
RX   PubMed=17115053; DOI=10.1038/nsmb1175;
RA   Jezyk M.R., Snyder J.T., Gershberg S., Worthylake D.K., Harden T.K.,
RA   Sondek J.;
RT   "Crystal structure of Rac1 bound to its effector phospholipase C-beta2.";
RL   Nat. Struct. Mol. Biol. 13:1135-1140(2006).
RN   [92]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 1-177 IN COMPLEX WITH DOCK2.
RX   PubMed=21613211; DOI=10.1074/jbc.m111.236455;
RA   Kulkarni K., Yang J., Zhang Z., Barford D.;
RT   "Multiple factors confer specific Cdc42 and Rac protein activation by
RT   dedicator of cytokinesis (DOCK) nucleotide exchange factors.";
RL   J. Biol. Chem. 286:25341-25351(2011).
RN   [93] {ECO:0007744|PDB:8Q0N}
RP   STRUCTURE BY ELECTRON MICROSCOPY (4.20 ANGSTROMS) IN COMPLEX WITH HACE1 AND
RP   GTP, UBIQUITINATION AT LYS-147, AND MUTAGENESIS OF GLN-61.
RX   PubMed=38332367; DOI=10.1038/s41594-023-01203-4;
RA   During J., Wolter M., Toplak J.J., Torres C., Dybkov O., Fokkens T.J.,
RA   Bohnsack K.E., Urlaub H., Steinchen W., Dienemann C., Lorenz S.;
RT   "Structural mechanisms of autoinhibition and substrate recognition by the
RT   ubiquitin ligase HACE1.";
RL   Nat. Struct. Mol. Biol. 31:364-377(2024).
RN   [94] {ECO:0007744|PDB:8WEJ}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.79 ANGSTROMS) OF 1-192 IN COMPLEX WITH
RP   CYBA; CYBB; NFC1; NFC2 AND GTP, SUBUNIT, FUNCTION, AND IDENTIFICATION OF
RP   THE NADPH OXIDASE COMPLEX.
RX   PubMed=38355798; DOI=10.1038/s41586-024-07056-1;
RA   Liu X., Shi Y., Liu R., Song K., Chen L.;
RT   "Structure of human phagocyte NADPH oxidase in the activated state.";
RL   Nature 627:189-195(2024).
CC   -!- FUNCTION: Plasma membrane-associated small GTPase which cycles between
CC       active GTP-bound and inactive GDP-bound states. In its active state,
CC       binds to a variety of effector proteins to regulate cellular responses
CC       such as secretory processes, phagocytosis of apoptotic cells,
CC       epithelial cell polarization, neurons adhesion, migration and
CC       differentiation, and growth-factor induced formation of membrane
CC       ruffles (PubMed:1643658, PubMed:22843693, PubMed:23512198,
CC       PubMed:28886345). Rac1 p21/rho GDI heterodimer is the active component
CC       of the cytosolic factor sigma 1, which is involved in stimulation of
CC       the NADPH oxidase activity in macrophages. Essential for the SPATA13-
CC       mediated regulation of cell migration and adhesion assembly and
CC       disassembly. Stimulates PKN2 kinase activity (PubMed:9121475). In
CC       concert with RAB7A, plays a role in regulating the formation of RBs
CC       (ruffled borders) in osteoclasts (PubMed:1643658). In podocytes,
CC       promotes nuclear shuttling of NR3C2; this modulation is required for a
CC       proper kidney functioning. Required for atypical chemokine receptor
CC       ACKR2-induced LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1)
CC       and for up-regulation of ACKR2 from endosomal compartment to cell
CC       membrane, increasing its efficiency in chemokine uptake and
CC       degradation. In neurons, is involved in dendritic spine formation and
CC       synaptic plasticity (By similarity). In hippocampal neurons, involved
CC       in spine morphogenesis and synapse formation, through local activation
CC       at synapses by guanine nucleotide exchange factors (GEFs), such as
CC       ARHGEF6/ARHGEF7/PIX (PubMed:12695502). In synapses, seems to mediate
CC       the regulation of F-actin cluster formation performed by SHANK3. In
CC       neurons, plays a crucial role in regulating GABA(A) receptor synaptic
CC       stability and hence GABAergic inhibitory synaptic transmission through
CC       its role in PAK1 activation and eventually F-actin stabilization (By
CC       similarity). Required for DSG3 translocation to cell-cell junctions,
CC       DSG3-mediated organization of cortical F-actin bundles and anchoring of
CC       actin at cell junctions; via interaction with DSG3 (PubMed:22796473).
CC       Subunit of the phagocyte NADPH oxidase complex that mediates the
CC       transfer of electrons from cytosolic NADPH to O2 to produce the
CC       superoxide anion (O2(-)) (PubMed:38355798).
CC       {ECO:0000250|UniProtKB:P63001, ECO:0000250|UniProtKB:Q6RUV5,
CC       ECO:0000269|PubMed:12695502, ECO:0000269|PubMed:1643658,
CC       ECO:0000269|PubMed:22796473, ECO:0000269|PubMed:22843693,
CC       ECO:0000269|PubMed:23512198, ECO:0000269|PubMed:28886345,
CC       ECO:0000269|PubMed:38355798, ECO:0000269|PubMed:9121475}.
CC   -!- FUNCTION: [Isoform B]: Isoform B has an accelerated GEF-independent
CC       GDP/GTP exchange and an impaired GTP hydrolysis, which is restored
CC       partially by GTPase-activating proteins (PubMed:14625275). It is able
CC       to bind to the GTPase-binding domain of PAK but not full-length PAK in
CC       a GTP-dependent manner, suggesting that the insertion does not
CC       completely abolish effector interaction (PubMed:14625275).
CC       {ECO:0000269|PubMed:14625275}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2;
CC         Evidence={ECO:0000269|PubMed:21565175};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19670;
CC         Evidence={ECO:0000305|PubMed:21565175};
CC   -!- ACTIVITY REGULATION: Regulated by guanine nucleotide exchange factors
CC       (GEFs) which promote the exchange of bound GDP for free GTP, GTPase
CC       activating proteins (GAPs) which increase the GTP hydrolysis activity,
CC       and GDP dissociation inhibitors which inhibit the dissociation of the
CC       nucleotide from the GTPase. GTP hydrolysis is stimulated by ARHGAP30.
CC       {ECO:0000269|PubMed:21565175}.
CC   -!- SUBUNIT: Interacts with NISCH. Interacts with PIP5K1A. Interacts with
CC       the GTP-bound form of RAB7A. Interacts with SRGAP2. Interacts with
CC       CYFIP1/SRA-1. Interacts with PLXNB3. Interacts with ARHGDIA; the
CC       interaction is induced by SEMA5A, mediated through PLXNB3 and
CC       inactivates and stabilizes RAC1. Interacts (GTP-bound form
CC       preferentially) with PKN2 (via the REM repeats); the interaction
CC       stimulates autophosphorylation and phosphorylation of PKN2. Interacts
CC       with the GEF proteins PREX1, RASGRF2, FARP1, FARP2, DOCK1, DOCK2 and
CC       DOCK7, which promote the exchange between GDP and GTP, and therefore
CC       activate it. Interacts with PARD6A, PARD6B and PARD6G in a GTP-
CC       dependent manner. Part of a quaternary complex containing PARD3, some
CC       PARD6 protein (PARD6A, PARD6B or PARD6G) and some atypical PKC protein
CC       (PRKCI or PRKCZ), which plays a central role in epithelial cell
CC       polarization. Found in a trimeric complex composed of DOCK1 and ELMO1,
CC       which plays a central role in phagocytosis of apoptotic cells.
CC       Interacts with RALBP1 via its effector domain. Interacts with PLXNB1.
CC       Part of a complex with MAP2K3, MAP3K3, CCM2 and DEF6. Interacts with
CC       BAIAP2, BAIAP2L1 and DEF6. Interacts with Y.pseudotuberculosis YPKA and
CC       PLCB2. Interacts with NOXA1. Interacts with ARHGEF2. Interacts with
CC       TBC1D2. Interacts with UNKL. Interacts with USP6. Interacts with
CC       SPATA13. Interacts with ARHGEF16; mediates activation of RAC1 by EPHA2.
CC       Interacts with ITGB4. Interacts with S100A8 and calprotectin
CC       (S100A8/9). Interacts with PACSIN2. Interacts with ITGB1BP1. Interacts
CC       (when active) with PPP5C (via TPR repeats); activates PPP5C phosphatase
CC       activity and translocates PPP5C to the cell membrane. Interacts with
CC       RAPH1 (via Ras associating and PH domains) (PubMed:18499456). Interacts
CC       with MTSS2 (via IMD domain); this interaction may be important to
CC       potentiate PDGF-induced RAC1 activation (PubMed:20875796). Interacts
CC       with PAK2 (PubMed:20696164). Interacts (GTP-bound form) with SH3RF1 and
CC       SH3RF3 (PubMed:20696164). Found in a complex with SH3RF1,
CC       MAPK8IP1/JIP1, MAP3K11/MLK3, MAP2K7/MKK7 and MAPK8/JNK1. Interacts
CC       (both active GTP- or inactive GDP-bound forms) with SH3RF2 (By
CC       similarity). Interacts (GTP-bound form preferentially) with CYRIB
CC       (PubMed:30250061, PubMed:31285585). Interacts with DOCK4 (via DOCKER
CC       domain); functions as a guanine nucleotide exchange factor (GEF) for
CC       RAC1 (PubMed:16464467). Interacts with GARRE1 (PubMed:31871319).
CC       Interacts with RAP1GDS1 (PubMed:12551911, PubMed:20709748). Interacts
CC       with TNFAIP8L2 (PubMed:32460619). May interact with ARHGAP36
CC       (PubMed:35986704). Interacts with CD151 and integrin beta1/ITGB1
CC       (PubMed:22843693). Interacts with DSG3; the interaction is required for
CC       DSG3 translocation to cell-cell junctions, organization of cortical F-
CC       actin bundles and actin anchoring at cell-cell junctions
CC       (PubMed:22796473). Component of the phagocyte NADPH oxidase complex
CC       composed of an obligatory core heterodimer formed by the membrane
CC       proteins CYBA and CYBB and the cytosolic regulatory subunits NCF1/p47-
CC       phox, NCF2/p67-phox, NCF4/p40-phox and the small GTPase RAC1 or RAC2
CC       (PubMed:38355798). Interacts with NCF2 (PubMed:11090627).
CC       {ECO:0000250|UniProtKB:P63001, ECO:0000250|UniProtKB:Q6RUV5,
CC       ECO:0000269|PubMed:10559471, ECO:0000269|PubMed:10954424,
CC       ECO:0000269|PubMed:11035813, ECO:0000269|PubMed:11090627,
CC       ECO:0000269|PubMed:11130063, ECO:0000269|PubMed:11130076,
CC       ECO:0000269|PubMed:11135665, ECO:0000269|PubMed:11163217,
CC       ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11346801,
CC       ECO:0000269|PubMed:11513578, ECO:0000269|PubMed:11807099,
CC       ECO:0000269|PubMed:12134158, ECO:0000269|PubMed:12551911,
CC       ECO:0000269|PubMed:12612085, ECO:0000269|PubMed:12716910,
CC       ECO:0000269|PubMed:15642721, ECO:0000269|PubMed:16464467,
CC       ECO:0000269|PubMed:16959567, ECO:0000269|PubMed:16982419,
CC       ECO:0000269|PubMed:17115053, ECO:0000269|PubMed:17121847,
CC       ECO:0000269|PubMed:17145773, ECO:0000269|PubMed:17430976,
CC       ECO:0000269|PubMed:18499456, ECO:0000269|PubMed:19403692,
CC       ECO:0000269|PubMed:19948726, ECO:0000269|PubMed:20116244,
CC       ECO:0000269|PubMed:20148946, ECO:0000269|PubMed:20679435,
CC       ECO:0000269|PubMed:20696164, ECO:0000269|PubMed:20709748,
CC       ECO:0000269|PubMed:20875796, ECO:0000269|PubMed:20974804,
CC       ECO:0000269|PubMed:21613211, ECO:0000269|PubMed:21693584,
CC       ECO:0000269|PubMed:22796473, ECO:0000269|PubMed:22843693,
CC       ECO:0000269|PubMed:23209303, ECO:0000269|PubMed:23375260,
CC       ECO:0000269|PubMed:23434736, ECO:0000269|PubMed:30250061,
CC       ECO:0000269|PubMed:31285585, ECO:0000269|PubMed:31871319,
CC       ECO:0000269|PubMed:32460619, ECO:0000269|PubMed:35986704,
CC       ECO:0000269|PubMed:38355798, ECO:0000269|PubMed:7673236,
CC       ECO:0000269|PubMed:9033596, ECO:0000269|PubMed:9121475,
CC       ECO:0000269|PubMed:9857026}.
CC   -!- INTERACTION:
CC       P63000; Q9NY61: AATF; NbExp=3; IntAct=EBI-413628, EBI-372428;
CC       P63000; P05067: APP; NbExp=3; IntAct=EBI-413628, EBI-77613;
CC       P63000; P53365: ARFIP2; NbExp=13; IntAct=EBI-413628, EBI-638194;
CC       P63000; Q92619: ARHGAP45; NbExp=3; IntAct=EBI-413628, EBI-2825900;
CC       P63000; P52565: ARHGDIA; NbExp=10; IntAct=EBI-413628, EBI-712693;
CC       P63000; Q14155: ARHGEF7; NbExp=8; IntAct=EBI-413628, EBI-717515;
CC       P63000; Q9UQB8: BAIAP2; NbExp=4; IntAct=EBI-413628, EBI-525456;
CC       P63000; Q14457: BECN1; NbExp=3; IntAct=EBI-413628, EBI-949378;
CC       P63000; Q13490: BIRC2; NbExp=2; IntAct=EBI-413628, EBI-514538;
CC       P63000; Q03135: CAV1; NbExp=3; IntAct=EBI-413628, EBI-603614;
CC       P63000; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-413628, EBI-396137;
CC       P63000; P52757: CHN2; NbExp=4; IntAct=EBI-413628, EBI-714925;
CC       P63000; Q14185: DOCK1; NbExp=10; IntAct=EBI-413628, EBI-446740;
CC       P63000; Q92608: DOCK2; NbExp=3; IntAct=EBI-413628, EBI-448771;
CC       P63000; O75369: FLNB; NbExp=2; IntAct=EBI-413628, EBI-352089;
CC       P63000; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-413628, EBI-618189;
CC       P63000; Q8IYU2: HACE1; NbExp=5; IntAct=EBI-413628, EBI-308277;
CC       P63000; Q8WUI4-6: HDAC7; NbExp=4; IntAct=EBI-413628, EBI-12094670;
CC       P63000; P46940: IQGAP1; NbExp=11; IntAct=EBI-413628, EBI-297509;
CC       P63000; P05412: JUN; NbExp=5; IntAct=EBI-413628, EBI-852823;
CC       P63000; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-413628, EBI-743960;
CC       P63000; Q6A162: KRT40; NbExp=3; IntAct=EBI-413628, EBI-10171697;
CC       P63000; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-413628, EBI-11985629;
CC       P63000; Q5S007: LRRK2; NbExp=5; IntAct=EBI-413628, EBI-5323863;
CC       P63000; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-413628, EBI-741037;
CC       P63000; Q13387-4: MAPK8IP2; NbExp=3; IntAct=EBI-413628, EBI-12345753;
CC       P63000; Q99750: MDFI; NbExp=3; IntAct=EBI-413628, EBI-724076;
CC       P63000; P41227: NAA10; NbExp=3; IntAct=EBI-413628, EBI-747693;
CC       P63000; Q01968: OCRL; NbExp=3; IntAct=EBI-413628, EBI-6148898;
CC       P63000; Q13153: PAK1; NbExp=26; IntAct=EBI-413628, EBI-1307;
CC       P63000; Q13177: PAK2; NbExp=5; IntAct=EBI-413628, EBI-1045887;
CC       P63000; Q9NPB6: PARD6A; NbExp=2; IntAct=EBI-413628, EBI-81876;
CC       P63000; Q9BYG5: PARD6B; NbExp=3; IntAct=EBI-413628, EBI-295391;
CC       P63000; Q9BYG4: PARD6G; NbExp=2; IntAct=EBI-413628, EBI-295417;
CC       P63000; Q9UHV9: PFDN2; NbExp=3; IntAct=EBI-413628, EBI-359873;
CC       P63000; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-413628, EBI-9090282;
CC       P63000; P19174: PLCG1; NbExp=7; IntAct=EBI-413628, EBI-79387;
CC       P63000; P00491: PNP; NbExp=3; IntAct=EBI-413628, EBI-712238;
CC       P63000; P41743: PRKCI; NbExp=3; IntAct=EBI-413628, EBI-286199;
CC       P63000; P52306: RAP1GDS1; NbExp=4; IntAct=EBI-413628, EBI-746389;
CC       P63000; Q92963: RIT1; NbExp=5; IntAct=EBI-413628, EBI-365845;
CC       P63000; P04271: S100B; NbExp=3; IntAct=EBI-413628, EBI-458391;
CC       P63000; Q01105: SET; NbExp=8; IntAct=EBI-413628, EBI-1053182;
CC       P63000; Q7Z6J0: SH3RF1; NbExp=2; IntAct=EBI-413628, EBI-311339;
CC       P63000; Q8TEJ3: SH3RF3; NbExp=6; IntAct=EBI-413628, EBI-7975674;
CC       P63000; P43405-2: SYK; NbExp=3; IntAct=EBI-413628, EBI-25892332;
CC       P63000; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-413628, EBI-17438286;
CC       P63000; Q6P589: TNFAIP8L2; NbExp=2; IntAct=EBI-413628, EBI-9073209;
CC       P63000; O60784-2: TOM1; NbExp=3; IntAct=EBI-413628, EBI-12117154;
CC       P63000; Q9H9P5: UNKL; NbExp=2; IntAct=EBI-413628, EBI-7797561;
CC       P63000; Q9Y6N9: USH1C; NbExp=3; IntAct=EBI-413628, EBI-954308;
CC       P63000; Q9BVJ6: UTP14A; NbExp=3; IntAct=EBI-413628, EBI-473284;
CC       P63000; P15498: VAV1; NbExp=2; IntAct=EBI-413628, EBI-625518;
CC       P63000; Q9UBQ0-2: VPS29; NbExp=3; IntAct=EBI-413628, EBI-11141397;
CC       P63000; P98170: XIAP; NbExp=3; IntAct=EBI-413628, EBI-517127;
CC       P63000; Q98PK8: smc; Xeno; NbExp=5; IntAct=EBI-413628, EBI-12740386;
CC       P63000-1; Q13153: PAK1; NbExp=3; IntAct=EBI-7212896, EBI-1307;
CC       P63000-1; Q8TCU6: PREX1; NbExp=2; IntAct=EBI-7212896, EBI-1046542;
CC       P63000-1; Q6P589: TNFAIP8L2; NbExp=6; IntAct=EBI-7212896, EBI-9073209;
CC       P63000-1; O75962-4: TRIO; NbExp=2; IntAct=EBI-7212896, EBI-15915736;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1643658,
CC       ECO:0000269|PubMed:22843693, ECO:0000269|PubMed:29074776}; Lipid-anchor
CC       {ECO:0000269|PubMed:1903399}; Cytoplasmic side
CC       {ECO:0000269|PubMed:1643658, ECO:0000269|PubMed:19948726}. Melanosome
CC       {ECO:0000269|PubMed:17081065, ECO:0000269|PubMed:19948726,
CC       ECO:0000269|PubMed:21693584}. Cytoplasm {ECO:0000269|PubMed:19948726,
CC       ECO:0000269|PubMed:29074776}. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:P63001}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P63001}. Synapse {ECO:0000250|UniProtKB:Q6RUV5}.
CC       Nucleus {ECO:0000269|PubMed:12551911}. Note=Inner surface of plasma
CC       membrane possibly with attachment requiring prenylation of the C-
CC       terminal cysteine (PubMed:1903399). Identified by mass spectrometry in
CC       melanosome fractions from stage I to stage IV (PubMed:17081065). Found
CC       in the ruffled border (a late endosomal-like compartment in the plasma
CC       membrane) of bone-resorbing osteoclasts. Localizes to the lamellipodium
CC       in a SH3RF1-dependent manner (By similarity). In macrophages,
CC       cytoplasmic location increases upon CSF1 stimulation (By similarity).
CC       Activation by GTP-binding promotes nuclear localization
CC       (PubMed:12551911). {ECO:0000250|UniProtKB:P63001,
CC       ECO:0000250|UniProtKB:Q6RUV5, ECO:0000269|PubMed:12551911,
CC       ECO:0000269|PubMed:17081065, ECO:0000269|PubMed:1903399}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A; Synonyms=Rac1A;
CC         IsoId=P63000-1, P15154-1; Sequence=Displayed;
CC       Name=B; Synonyms=Rac1B, Rac1ins;
CC         IsoId=P63000-2, P15154-2; Sequence=VSP_005710;
CC   -!- TISSUE SPECIFICITY: Isoform B is predominantly identified in skin and
CC       epithelial tissues from the intestinal tract. Its expression is
CC       elevated in colorectal tumors at various stages of neoplastic
CC       progression, as compared to their respective adjacent tissues.
CC   -!- DOMAIN: The effector region mediates interaction with DEF6.
CC       {ECO:0000269|PubMed:17121847}.
CC   -!- PTM: GTP-bound active form is ubiquitinated at Lys-147 by HACE1,
CC       leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:18093184, ECO:0000269|PubMed:22036506,
CC       ECO:0000269|PubMed:38332367}.
CC   -!- PTM: Phosphorylated by AKT at Ser-71. {ECO:0000269|PubMed:10617634}.
CC   -!- PTM: Ubiquitinated at Lys-166 in a FBXL19-mediated manner; leading to
CC       proteasomal degradation. {ECO:0000269|PubMed:23512198}.
CC   -!- PTM: (Microbial infection) AMPylation at Tyr-32 and Thr-35 are mediated
CC       by bacterial enzymes in case of infection by H.somnus and
CC       V.parahaemolyticus, respectively. AMPylation occurs in the effector
CC       region and leads to inactivation of the GTPase activity by preventing
CC       the interaction with downstream effectors, thereby inhibiting actin
CC       assembly in infected cells. It is unclear whether some human enzyme
CC       mediates AMPylation; FICD has such ability in vitro but additional
CC       experiments remain to be done to confirm results in vivo.
CC       {ECO:0000269|PubMed:19039103, ECO:0000269|PubMed:19362538}.
CC   -!- PTM: (Microbial infection) Glycosylated at Tyr-32 by Photorhabdus
CC       asymbiotica toxin PAU_02230. Mono-O-GlcNAcylation by PAU_02230 inhibits
CC       downstream signaling by an impaired interaction with diverse regulator
CC       and effector proteins of Rac and leads to actin disassembly.
CC       {ECO:0000269|PubMed:24141704}.
CC   -!- PTM: (Microbial infection) Glucosylated at Thr-35 by C.difficile toxins
CC       TcdA and TcdB in the colonic epithelium, and by P.sordellii toxin TcsL
CC       in the vascular endothelium (PubMed:19744486, PubMed:24905543,
CC       PubMed:7775453, PubMed:7777059, PubMed:8626575). Monoglucosylation
CC       completely prevents the recognition of the downstream effector,
CC       blocking the GTPases in their inactive form, leading to actin
CC       cytoskeleton disruption and cell death, resulting in the loss of
CC       colonic epithelial barrier function (PubMed:7775453, PubMed:7777059).
CC       {ECO:0000269|PubMed:19744486, ECO:0000269|PubMed:24905543,
CC       ECO:0000269|PubMed:7775453, ECO:0000269|PubMed:7777059,
CC       ECO:0000269|PubMed:8626575}.
CC   -!- PTM: (Microbial infection) Glycosylated (O-GlcNAcylated) at Thr-35 by
CC       C.novyi toxin TcdA (PubMed:8810274). O-GlcNAcylation completely
CC       prevents the recognition of the downstream effector, blocking the
CC       GTPases in their inactive form, leading to actin cytoskeleton
CC       disruption (PubMed:8810274). {ECO:0000269|PubMed:8810274}.
CC   -!- PTM: (Microbial infection) Palmitoylated by the N-epsilon-fatty
CC       acyltransferase F2 chain of V.cholerae toxin RtxA (PubMed:29074776).
CC       Palmitoylation inhibits activation by guanine nucleotide exchange
CC       factors (GEFs), preventing Rho GTPase signaling (PubMed:29074776).
CC       {ECO:0000269|PubMed:29074776}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 48
CC       (MRD48) [MIM:617751]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period. MRD48
CC       patients manifest global developmental delay and moderate to severe
CC       intellectual disability. {ECO:0000269|PubMed:28886345}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Rho family.
CC       {ECO:0000305}.
CC   -!- CAUTION: The interaction between DSCAM, PAK1 and RAC1 has been
CC       described. This article has been withdrawn by the authors.
CC       {ECO:0000305|PubMed:15169762, ECO:0000305|PubMed:26048998}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAZ80485.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M29870; AAA36537.1; -; mRNA.
DR   EMBL; M31467; AAA36544.1; -; mRNA.
DR   EMBL; AJ132694; CAA10732.1; -; mRNA.
DR   EMBL; AJ132695; CAB53579.5; -; Genomic_DNA.
DR   EMBL; AJ132695; CAA10733.6; -; Genomic_DNA.
DR   EMBL; AF136373; AAD30547.1; -; mRNA.
DR   EMBL; AY279384; AAQ16632.1; -; mRNA.
DR   EMBL; AF498964; AAM21111.1; -; mRNA.
DR   EMBL; BT007121; AAP35785.1; -; mRNA.
DR   EMBL; DQ165078; AAZ80485.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AC009412; AAS07511.1; -; Genomic_DNA.
DR   EMBL; AC009412; AAS07512.1; -; Genomic_DNA.
DR   EMBL; BC004247; AAH04247.1; -; mRNA.
DR   EMBL; BC050687; AAH50687.1; -; mRNA.
DR   EMBL; BC107748; AAI07749.1; -; mRNA.
DR   CCDS; CCDS5348.1; -.
DR   CCDS; CCDS5349.1; -. [P63000-2]
DR   PIR; A34788; TVHUC1.
DR   RefSeq; NP_008839.2; NM_006908.4. [P63000-1]
DR   RefSeq; NP_061485.1; NM_018890.3. [P63000-2]
DR   PDB; 1E96; X-ray; 2.40 A; A=2-192.
DR   PDB; 1FOE; X-ray; 2.80 A; B/D/F/H=1-177.
DR   PDB; 1G4U; X-ray; 2.30 A; R=1-184.
DR   PDB; 1HE1; X-ray; 2.00 A; C/D=2-176.
DR   PDB; 1HH4; X-ray; 2.70 A; A/B=2-192.
DR   PDB; 1I4D; X-ray; 2.50 A; D=1-192.
DR   PDB; 1I4L; X-ray; 2.70 A; D=1-192.
DR   PDB; 1I4T; X-ray; 2.60 A; D=1-192.
DR   PDB; 1MH1; X-ray; 1.38 A; A=2-184.
DR   PDB; 1RYF; X-ray; 1.75 A; A/B=1-182.
DR   PDB; 1RYH; X-ray; 1.75 A; A/B=1-182.
DR   PDB; 2FJU; X-ray; 2.20 A; A=1-177.
DR   PDB; 2H7V; X-ray; 2.60 A; A/B=1-184.
DR   PDB; 2NZ8; X-ray; 2.00 A; A=1-177.
DR   PDB; 2P2L; X-ray; 1.90 A; A/B/C=1-184.
DR   PDB; 2RMK; NMR; -; A=1-192.
DR   PDB; 2VRW; X-ray; 1.85 A; A=1-184.
DR   PDB; 2WKP; X-ray; 1.90 A; A=4-180.
DR   PDB; 2WKQ; X-ray; 1.60 A; A=4-180.
DR   PDB; 2WKR; X-ray; 2.20 A; A=4-180.
DR   PDB; 2YIN; X-ray; 2.70 A; C/D=1-177.
DR   PDB; 3B13; X-ray; 3.01 A; B/D=1-177.
DR   PDB; 3BJI; X-ray; 2.60 A; C/D=1-177.
DR   PDB; 3RYT; X-ray; 3.58 A; C=1-177.
DR   PDB; 3SBD; X-ray; 2.10 A; A/B=2-177.
DR   PDB; 3SBE; X-ray; 2.60 A; A=2-177.
DR   PDB; 3SU8; X-ray; 3.20 A; A=1-177.
DR   PDB; 3SUA; X-ray; 4.39 A; A/B/C=1-177.
DR   PDB; 3TH5; X-ray; 2.30 A; A/B=2-177.
DR   PDB; 4GZL; X-ray; 2.00 A; A/B=2-177.
DR   PDB; 4GZM; X-ray; 2.80 A; A/B=2-177.
DR   PDB; 4YON; X-ray; 1.95 A; B=1-177.
DR   PDB; 5FI0; X-ray; 3.28 A; B/D/F/H=1-192.
DR   PDB; 5HZH; X-ray; 2.60 A; A=1-180.
DR   PDB; 5N6O; X-ray; 2.59 A; A/B=2-177.
DR   PDB; 5O33; X-ray; 1.64 A; A=1-177.
DR   PDB; 5QQD; X-ray; 1.91 A; A=1-177.
DR   PDB; 5QQE; X-ray; 1.95 A; A=1-177.
DR   PDB; 5QQF; X-ray; 2.26 A; A=1-177.
DR   PDB; 5QQG; X-ray; 2.23 A; A=1-177.
DR   PDB; 5QQH; X-ray; 2.09 A; A=1-177.
DR   PDB; 5QQI; X-ray; 2.08 A; A=1-177.
DR   PDB; 5QQJ; X-ray; 1.90 A; A=1-177.
DR   PDB; 5QQK; X-ray; 2.24 A; A=1-177.
DR   PDB; 5QQL; X-ray; 2.25 A; A=1-177.
DR   PDB; 5QQM; X-ray; 2.02 A; A=1-177.
DR   PDB; 5QQN; X-ray; 2.26 A; A=1-177.
DR   PDB; 5QU9; X-ray; 2.00 A; A=1-177.
DR   PDB; 6AGP; NMR; -; A=1-181.
DR   PDB; 6BC1; X-ray; 2.90 A; A/B=2-177.
DR   PDB; 6TGC; EM; 4.10 A; C/F=1-192.
DR   PDB; 6X1G; X-ray; 1.60 A; B/D=1-177.
DR   PDB; 7AJK; X-ray; 3.10 A; BBB=2-177.
DR   PDB; 7DPA; EM; 3.80 A; B/E=1-177.
DR   PDB; 7SJ4; EM; 2.86 A; B=1-192.
DR   PDB; 7USD; EM; 3.00 A; F=1-188.
DR   PDB; 7USE; EM; 3.00 A; F/G=1-188.
DR   PDB; 8I5V; X-ray; 1.73 A; B=1-177.
DR   PDB; 8I5W; X-ray; 2.43 A; B=1-177.
DR   PDB; 8Q0N; EM; 4.20 A; C=1-192.
DR   PDB; 8WEJ; EM; 2.79 A; E=1-192.
DR   PDB; 8ZJ2; EM; 4.66 A; C/G=1-177.
DR   PDB; 8ZJI; EM; 4.23 A; C/F=1-177.
DR   PDB; 8ZJJ; EM; 4.23 A; C/F=1-177.
DR   PDB; 8ZJK; EM; 4.23 A; C/F=1-177.
DR   PDB; 8ZJL; EM; 4.31 A; C/F=1-177.
DR   PDB; 8ZJM; EM; 4.52 A; C/F=1-177.
DR   PDBsum; 1E96; -.
DR   PDBsum; 1FOE; -.
DR   PDBsum; 1G4U; -.
DR   PDBsum; 1HE1; -.
DR   PDBsum; 1HH4; -.
DR   PDBsum; 1I4D; -.
DR   PDBsum; 1I4L; -.
DR   PDBsum; 1I4T; -.
DR   PDBsum; 1MH1; -.
DR   PDBsum; 1RYF; -.
DR   PDBsum; 1RYH; -.
DR   PDBsum; 2FJU; -.
DR   PDBsum; 2H7V; -.
DR   PDBsum; 2NZ8; -.
DR   PDBsum; 2P2L; -.
DR   PDBsum; 2RMK; -.
DR   PDBsum; 2VRW; -.
DR   PDBsum; 2WKP; -.
DR   PDBsum; 2WKQ; -.
DR   PDBsum; 2WKR; -.
DR   PDBsum; 2YIN; -.
DR   PDBsum; 3B13; -.
DR   PDBsum; 3BJI; -.
DR   PDBsum; 3RYT; -.
DR   PDBsum; 3SBD; -.
DR   PDBsum; 3SBE; -.
DR   PDBsum; 3SU8; -.
DR   PDBsum; 3SUA; -.
DR   PDBsum; 3TH5; -.
DR   PDBsum; 4GZL; -.
DR   PDBsum; 4GZM; -.
DR   PDBsum; 4YON; -.
DR   PDBsum; 5FI0; -.
DR   PDBsum; 5HZH; -.
DR   PDBsum; 5N6O; -.
DR   PDBsum; 5O33; -.
DR   PDBsum; 5QQD; -.
DR   PDBsum; 5QQE; -.
DR   PDBsum; 5QQF; -.
DR   PDBsum; 5QQG; -.
DR   PDBsum; 5QQH; -.
DR   PDBsum; 5QQI; -.
DR   PDBsum; 5QQJ; -.
DR   PDBsum; 5QQK; -.
DR   PDBsum; 5QQL; -.
DR   PDBsum; 5QQM; -.
DR   PDBsum; 5QQN; -.
DR   PDBsum; 5QU9; -.
DR   PDBsum; 6AGP; -.
DR   PDBsum; 6BC1; -.
DR   PDBsum; 6TGC; -.
DR   PDBsum; 6X1G; -.
DR   PDBsum; 7AJK; -.
DR   PDBsum; 7DPA; -.
DR   PDBsum; 7SJ4; -.
DR   PDBsum; 7USD; -.
DR   PDBsum; 7USE; -.
DR   PDBsum; 8I5V; -.
DR   PDBsum; 8I5W; -.
DR   PDBsum; 8Q0N; -.
DR   PDBsum; 8WEJ; -.
DR   PDBsum; 8ZJ2; -.
DR   PDBsum; 8ZJI; -.
DR   PDBsum; 8ZJJ; -.
DR   PDBsum; 8ZJK; -.
DR   PDBsum; 8ZJL; -.
DR   PDBsum; 8ZJM; -.
DR   AlphaFoldDB; P63000; -.
DR   BMRB; P63000; -.
DR   EMDB; EMD-10498; -.
DR   EMDB; EMD-18056; -.
DR   EMDB; EMD-25153; -.
DR   EMDB; EMD-26733; -.
DR   EMDB; EMD-26734; -.
DR   EMDB; EMD-30802; -.
DR   EMDB; EMD-37593; -.
DR   EMDB; EMD-60136; -.
DR   EMDB; EMD-60146; -.
DR   EMDB; EMD-60147; -.
DR   EMDB; EMD-60148; -.
DR   EMDB; EMD-60149; -.
DR   EMDB; EMD-60150; -.
DR   SMR; P63000; -.
DR   BioGRID; 111817; 1020.
DR   ComplexPortal; CPX-1017; Phagocyte NADPH oxidase complex, RAC1 variant.
DR   CORUM; P63000; -.
DR   DIP; DIP-29260N; -.
DR   IntAct; P63000; 277.
DR   MINT; P63000; -.
DR   STRING; 9606.ENSP00000348461; -.
DR   BindingDB; P63000; -.
DR   ChEMBL; CHEMBL6094; -.
DR   DrugBank; DB00993; Azathioprine.
DR   DrugBank; DB00514; Dextromethorphan.
DR   DrugBank; DB04315; Guanosine-5'-Diphosphate.
DR   DrugCentral; P63000; -.
DR   GlyCosmos; P63000; 2 sites, No reported glycans.
DR   GlyGen; P63000; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P63000; -.
DR   MetOSite; P63000; -.
DR   PhosphoSitePlus; P63000; -.
DR   SwissPalm; P63000; -.
DR   BioMuta; RAC1; -.
DR   DMDM; 51702787; -.
DR   jPOST; P63000; -.
DR   MassIVE; P63000; -.
DR   PaxDb; 9606-ENSP00000348461; -.
DR   PeptideAtlas; P63000; -.
DR   ProteomicsDB; 57467; -.
DR   ProteomicsDB; 57468; -. [P63000-2]
DR   Pumba; P63000; -.
DR   Antibodypedia; 4545; 869 antibodies from 41 providers.
DR   CPTC; P63000; 2 antibodies.
DR   DNASU; 5879; -.
DR   Ensembl; ENST00000348035.9; ENSP00000258737.7; ENSG00000136238.20. [P63000-1]
DR   Ensembl; ENST00000356142.4; ENSP00000348461.4; ENSG00000136238.20. [P63000-2]
DR   GeneID; 5879; -.
DR   KEGG; hsa:5879; -.
DR   MANE-Select; ENST00000348035.9; ENSP00000258737.7; NM_006908.5; NP_008839.2.
DR   UCSC; uc003spw.4; human.
DR   AGR; HGNC:9801; -.
DR   CTD; 5879; -.
DR   DisGeNET; 5879; -.
DR   GeneCards; RAC1; -.
DR   HGNC; HGNC:9801; RAC1.
DR   HPA; ENSG00000136238; Low tissue specificity.
DR   MalaCards; RAC1; -.
DR   MIM; 602048; gene.
DR   MIM; 617751; phenotype.
DR   neXtProt; NX_P63000; -.
DR   OpenTargets; ENSG00000136238; -.
DR   Orphanet; 500159; Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom.
DR   PharmGKB; PA34162; -.
DR   VEuPathDB; HostDB:ENSG00000136238; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   GeneTree; ENSGT00940000153500; -.
DR   HOGENOM; CLU_041217_21_3_1; -.
DR   InParanoid; P63000; -.
DR   OMA; PFCDVFL; -.
DR   OrthoDB; 8953216at2759; -.
DR   PhylomeDB; P63000; -.
DR   TreeFam; TF101109; -.
DR   BRENDA; 3.6.5.2; 2681.
DR   PathwayCommons; P63000; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-4086400; PCP/CE pathway.
DR   Reactome; R-HSA-416550; Sema4D mediated inhibition of cell attachment and migration.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   Reactome; R-HSA-428540; Activation of RAC1.
DR   Reactome; R-HSA-428543; Inactivation of CDC42 and RAC1.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5625900; RHO GTPases activate CIT.
DR   Reactome; R-HSA-5625970; RHO GTPases activate KTN1.
DR   Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8875555; MET activates RAP1 and RAC1.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9032759; NTRK2 activates RAC1.
DR   Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5.
DR   Reactome; R-HSA-9619229; Activation of RAC1 downstream of NMDARs.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9673324; WNT5:FZD7-mediated leishmania damping.
DR   Reactome; R-HSA-9748787; Azathioprine ADME.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P63000; -.
DR   SIGNOR; P63000; -.
DR   BioGRID-ORCS; 5879; 622 hits in 1180 CRISPR screens.
DR   ChiTaRS; RAC1; human.
DR   EvolutionaryTrace; P63000; -.
DR   GeneWiki; RAC1; -.
DR   GenomeRNAi; 5879; -.
DR   Pharos; P63000; Tbio.
DR   PRO; PR:P63000; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P63000; protein.
DR   Bgee; ENSG00000136238; Expressed in esophagus squamous epithelium and 210 other cell types or tissues.
DR   ExpressionAtlas; P63000; baseline and differential.
DR   GO; GO:0005938; C:cell cortex; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0043020; C:NADPH oxidase complex; NAS:ComplexPortal.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR   GO; GO:0055038; C:recycling endosome membrane; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:FlyBase.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:1990606; F:membrane scission GTPase motor activity; IEA:RHEA.
DR   GO; GO:0019901; F:protein kinase binding; IPI:CAFA.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0051022; F:Rho GDP-dissociation inhibitor binding; ISS:UniProtKB.
DR   GO; GO:0031996; F:thioesterase binding; IPI:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IGI:MGI.
DR   GO; GO:0007015; P:actin filament organization; IMP:UniProtKB.
DR   GO; GO:0030041; P:actin filament polymerization; TAS:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IDA:UniProt.
DR   GO; GO:0048870; P:cell motility; IDA:UniProtKB.
DR   GO; GO:0030031; P:cell projection assembly; IBA:GO_Central.
DR   GO; GO:0007160; P:cell-matrix adhesion; NAS:BHF-UCL.
DR   GO; GO:0030865; P:cortical cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0007163; P:establishment or maintenance of cell polarity; IBA:GO_Central.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; IMP:CAFA.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0030032; P:lamellipodium assembly; IMP:UniProtKB.
DR   GO; GO:0051668; P:localization within membrane; IMP:BHF-UCL.
DR   GO; GO:0008045; P:motor neuron axon guidance; IBA:GO_Central.
DR   GO; GO:0010764; P:negative regulation of fibroblast migration; IDA:BHF-UCL.
DR   GO; GO:0032707; P:negative regulation of interleukin-23 production; IDA:BHF-UCL.
DR   GO; GO:0048261; P:negative regulation of receptor-mediated endocytosis; TAS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:1903348; P:positive regulation of bicellular tight junction assembly; IMP:UniProtKB.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IGI:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; IDA:MGI.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:CAFA.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; TAS:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:UniProtKB.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0016601; P:Rac protein signal transduction; IBA:GO_Central.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   GO; GO:0008361; P:regulation of cell size; IMP:UniProtKB.
DR   GO; GO:0010310; P:regulation of hydrogen peroxide metabolic process; TAS:BHF-UCL.
DR   GO; GO:0010591; P:regulation of lamellipodium assembly; IGI:CAFA.
DR   GO; GO:1902622; P:regulation of neutrophil migration; IBA:GO_Central.
DR   GO; GO:0045428; P:regulation of nitric oxide biosynthetic process; ISS:ARUK-UCL.
DR   GO; GO:0060263; P:regulation of respiratory burst; IDA:BHF-UCL.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; IGI:CAFA.
DR   GO; GO:0045730; P:respiratory burst; NAS:ComplexPortal.
DR   GO; GO:0009611; P:response to wounding; TAS:ProtInc.
DR   GO; GO:0097178; P:ruffle assembly; IMP:UniProtKB.
DR   GO; GO:0031529; P:ruffle organization; IDA:MGI.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007264; P:small GTPase-mediated signal transduction; IMP:BHF-UCL.
DR   GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; NAS:ParkinsonsUK-UCL.
DR   CDD; cd01871; Rac1_like; 1.
DR   FunFam; 3.40.50.300:FF:000088; Ras-related C3 botulinum toxin substrate 1; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   IDEAL; IID00312; -.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   NCBIfam; TIGR00231; small_GTP; 1.
DR   PANTHER; PTHR24072; RHO FAMILY GTPASE; 1.
DR   Pfam; PF00071; Ras; 1.
DR   PRINTS; PR00449; RASTRNSFRMNG.
DR   SMART; SM00175; RAB; 1.
DR   SMART; SM00173; RAS; 1.
DR   SMART; SM00174; RHO; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Cell projection;
KW   Cytoplasm; Disease variant; Glycoprotein; GTP-binding; Hydrolase;
KW   Intellectual disability; Isopeptide bond; Lipoprotein; Membrane;
KW   Methylation; Nucleotide-binding; Nucleus; Palmitate; Phosphoprotein;
KW   Prenylation; Proteomics identification; Reference proteome; Synapse;
KW   Ubl conjugation.
FT   CHAIN           1..189
FT                   /note="Ras-related C3 botulinum toxin substrate 1"
FT                   /id="PRO_0000042036"
FT   PROPEP          190..192
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000305|PubMed:1903399"
FT                   /id="PRO_0000042037"
FT   MOTIF           32..40
FT                   /note="Effector region"
FT                   /evidence="ECO:0000255"
FT   MOTIF           179..188
FT                   /note="Polybasic region; required for nuclear import"
FT                   /evidence="ECO:0000269|PubMed:12551911"
FT   BINDING         12
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:38332367,
FT                   ECO:0007744|PDB:8Q0N"
FT   BINDING         13
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR,
FT                   ECO:0007744|PDB:8Q0N, ECO:0007744|PDB:8WEJ"
FT   BINDING         14
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0007744|PDB:1E96,
FT                   ECO:0007744|PDB:2WKP, ECO:0007744|PDB:2WKQ,
FT                   ECO:0007744|PDB:2WKR, ECO:0007744|PDB:8Q0N"
FT   BINDING         15
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0007744|PDB:1E96,
FT                   ECO:0007744|PDB:2WKP, ECO:0007744|PDB:2WKQ,
FT                   ECO:0007744|PDB:2WKR, ECO:0007744|PDB:8Q0N"
FT   BINDING         16
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR,
FT                   ECO:0007744|PDB:8Q0N, ECO:0007744|PDB:8WEJ"
FT   BINDING         17
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR,
FT                   ECO:0007744|PDB:8Q0N, ECO:0007744|PDB:8WEJ"
FT   BINDING         18
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR,
FT                   ECO:0007744|PDB:8Q0N, ECO:0007744|PDB:8WEJ"
FT   BINDING         31
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0007744|PDB:1E96,
FT                   ECO:0007744|PDB:2WKP, ECO:0007744|PDB:2WKQ,
FT                   ECO:0007744|PDB:2WKR, ECO:0007744|PDB:8Q0N"
FT   BINDING         32
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0007744|PDB:1E96,
FT                   ECO:0007744|PDB:2WKP, ECO:0007744|PDB:2WKQ,
FT                   ECO:0007744|PDB:2WKR, ECO:0007744|PDB:8Q0N"
FT   BINDING         34
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0007744|PDB:1E96,
FT                   ECO:0007744|PDB:2WKP, ECO:0007744|PDB:2WKQ,
FT                   ECO:0007744|PDB:2WKR, ECO:0007744|PDB:8Q0N"
FT   BINDING         35
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR,
FT                   ECO:0007744|PDB:8Q0N, ECO:0007744|PDB:8WEJ"
FT   BINDING         59
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:38332367,
FT                   ECO:0007744|PDB:8Q0N"
FT   BINDING         60
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR"
FT   BINDING         116
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0007744|PDB:1E96,
FT                   ECO:0007744|PDB:2WKP, ECO:0007744|PDB:2WKQ,
FT                   ECO:0007744|PDB:2WKR, ECO:0007744|PDB:8Q0N"
FT   BINDING         118
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0007744|PDB:1E96,
FT                   ECO:0007744|PDB:2WKP, ECO:0007744|PDB:2WKQ,
FT                   ECO:0007744|PDB:2WKR, ECO:0007744|PDB:8Q0N"
FT   BINDING         119
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:38332367,
FT                   ECO:0007744|PDB:8Q0N"
FT   BINDING         158
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:8WEJ"
FT   BINDING         159
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR,
FT                   ECO:0007744|PDB:8Q0N, ECO:0007744|PDB:8WEJ"
FT   BINDING         160
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:11090627,
FT                   ECO:0000269|PubMed:38332367, ECO:0000269|PubMed:38355798,
FT                   ECO:0007744|PDB:1E96, ECO:0007744|PDB:2WKP,
FT                   ECO:0007744|PDB:2WKQ, ECO:0007744|PDB:2WKR,
FT                   ECO:0007744|PDB:8Q0N, ECO:0007744|PDB:8WEJ"
FT   MOD_RES         32
FT                   /note="(Microbial infection) O-AMP-tyrosine; by Haemophilus
FT                   IbpA; alternate"
FT                   /evidence="ECO:0000269|PubMed:19362538"
FT   MOD_RES         35
FT                   /note="(Microbial infection) O-AMP-threonine; by Vibrio
FT                   VopS"
FT                   /evidence="ECO:0000269|PubMed:19039103"
FT   MOD_RES         71
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10617634"
FT   MOD_RES         189
FT                   /note="Cysteine methyl ester"
FT                   /evidence="ECO:0000250|UniProtKB:P61585"
FT   LIPID           183
FT                   /note="(Microbial infection) N6-palmitoyl lysine"
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   LIPID           184
FT                   /note="(Microbial infection) N6-palmitoyl lysine"
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   LIPID           189
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:1903399"
FT   CARBOHYD        32
FT                   /note="(Microbial infection) O-linked (GlcNAc) tyrosine; by
FT                   Photorhabdus PAU_02230; alternate"
FT                   /evidence="ECO:0000269|PubMed:24141704"
FT   CARBOHYD        35
FT                   /note="(Microbial infection) O-alpha-linked (GlcNAc)
FT                   threonine; by C.novyi toxin TcdA; alternate"
FT                   /evidence="ECO:0000269|PubMed:8810274"
FT   CARBOHYD        35
FT                   /note="(Microbial infection) O-linked (Glc) threonine; by
FT                   C.difficile toxins TcdA and TcdB, and by P.sordellii toxin
FT                   TcsL; alternate"
FT                   /evidence="ECO:0000269|PubMed:19744486,
FT                   ECO:0000269|PubMed:24905543, ECO:0000269|PubMed:7775453,
FT                   ECO:0000269|PubMed:7777059"
FT   CROSSLNK        147
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18093184,
FT                   ECO:0000269|PubMed:38332367"
FT   CROSSLNK        166
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:23512198"
FT   VAR_SEQ         75
FT                   /note="T -> TVGETYGKDITSRGKDKPIA (in isoform B)"
FT                   /evidence="ECO:0000303|PubMed:10597294,
FT                   ECO:0000303|PubMed:11062023, ECO:0000303|Ref.5"
FT                   /id="VSP_005710"
FT   VARIANT         18
FT                   /note="C -> Y (in MRD48; decreased substrate
FT                   adhesion-dependent cell spreading; dominant-negative
FT                   effect; reduced neuronal proliferation;
FT                   dbSNP:rs1554263326)"
FT                   /evidence="ECO:0000269|PubMed:28886345"
FT                   /id="VAR_080454"
FT   VARIANT         26
FT                   /note="N -> D (in dbSNP:rs2115193158)"
FT                   /id="VAR_014540"
FT   VARIANT         28
FT                   /note="F -> L (in dbSNP:rs2115193183)"
FT                   /id="VAR_014541"
FT   VARIANT         39
FT                   /note="N -> S (in MRD48; decreased substrate
FT                   adhesion-dependent cell spreading; dominant-negative
FT                   effect; reduced neuronal proliferation;
FT                   dbSNP:rs1554263624)"
FT                   /evidence="ECO:0000269|PubMed:28886345"
FT                   /id="VAR_080455"
FT   VARIANT         51
FT                   /note="V -> L (in MRD48; uncertain significance;
FT                   dbSNP:rs1554263625)"
FT                   /evidence="ECO:0000269|PubMed:28886345"
FT                   /id="VAR_080456"
FT   VARIANT         51
FT                   /note="V -> M (in MRD48; decreased substrate
FT                   adhesion-dependent cell spreading; weak dominant-negative
FT                   effect; dbSNP:rs1554263625)"
FT                   /evidence="ECO:0000269|PubMed:28886345"
FT                   /id="VAR_080457"
FT   VARIANT         59
FT                   /note="A -> T (in dbSNP:rs5837)"
FT                   /id="VAR_014542"
FT   VARIANT         63
FT                   /note="D -> G (in dbSNP:rs5831)"
FT                   /id="VAR_014543"
FT   VARIANT         64
FT                   /note="Y -> D (in MRD48; increased substrate
FT                   adhesion-dependent cell spreading; constitutively active;
FT                   dbSNP:rs1554263626)"
FT                   /evidence="ECO:0000269|PubMed:28886345"
FT                   /id="VAR_080458"
FT   VARIANT         73
FT                   /note="P -> L (in MRD48; decreased substrate
FT                   adhesion-dependent cell spreading; weak dominant-negative
FT                   effect; dbSNP:rs2115201441)"
FT                   /evidence="ECO:0000269|PubMed:28886345"
FT                   /id="VAR_080459"
FT   VARIANT         93
FT                   /note="V -> G (in dbSNP:rs5826)"
FT                   /id="VAR_014545"
FT   VARIANT         93
FT                   /note="V -> I (in dbSNP:rs5825)"
FT                   /id="VAR_014544"
FT   VARIANT         108
FT                   /note="T -> I (in dbSNP:rs2115217353)"
FT                   /id="VAR_014546"
FT   VARIANT         130
FT                   /note="K -> R (in dbSNP:rs5828)"
FT                   /id="VAR_014547"
FT   VARIANT         133
FT                   /note="K -> E (in dbSNP:rs5835)"
FT                   /id="VAR_014548"
FT   VARIANT         135
FT                   /note="T -> I (in dbSNP:rs11540455)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_033303"
FT   VARIANT         157
FT                   /note="C -> Y (in MRD48; decreased substrate
FT                   adhesion-dependent cell spreading; weak dominant-negative
FT                   effect; dbSNP:rs1554264268)"
FT                   /evidence="ECO:0000269|PubMed:28886345"
FT                   /id="VAR_080460"
FT   VARIANT         180
FT                   /note="P -> S (in dbSNP:rs16063)"
FT                   /id="VAR_014549"
FT   VARIANT         182
FT                   /note="V -> E (in dbSNP:rs5836)"
FT                   /id="VAR_014550"
FT   MUTAGEN         12
FT                   /note="G->V: Constitutively active. Interacts with PARD6
FT                   proteins. Increases nuclear localization and up-regulates
FT                   transcriptional activity of NR3C2. Doesn't interact with
FT                   CYRIB. Increases interaction with GARRE1."
FT                   /evidence="ECO:0000269|PubMed:11260256,
FT                   ECO:0000269|PubMed:19029984, ECO:0000269|PubMed:30250061,
FT                   ECO:0000269|PubMed:31871319"
FT   MUTAGEN         17
FT                   /note="T->N: Constitutively inactivated. Abolishes
FT                   interaction with PARD6 proteins. No effect on NR3C2
FT                   transcriptional activity. No interaction with PPP5C.
FT                   Doesn't activate PPP5C phosphatase activity and translocate
FT                   PPP5C to the plasma membrane. Doesn't interact with CYRIB."
FT                   /evidence="ECO:0000269|PubMed:11260256,
FT                   ECO:0000269|PubMed:19029984, ECO:0000269|PubMed:19948726,
FT                   ECO:0000269|PubMed:30250061"
FT   MUTAGEN         30
FT                   /note="G->V: No interaction with PPP5C; when associated
FT                   with L-61. Translocates to the plasma membrane; also when
FT                   associated with L-61."
FT                   /evidence="ECO:0000269|PubMed:19948726"
FT   MUTAGEN         32
FT                   /note="Y->F: Abolishes AMPylation by Haemophilus IbpA."
FT                   /evidence="ECO:0000269|PubMed:19362538"
FT   MUTAGEN         35
FT                   /note="T->A: Abolishes AMPylation by Vibrio VopS."
FT                   /evidence="ECO:0000269|PubMed:19039103,
FT                   ECO:0000269|PubMed:19948726"
FT   MUTAGEN         35
FT                   /note="T->S: No interaction with PPP5C; when associated
FT                   with L-61. Translocates to the plasma membrane; also when
FT                   associated with L-61."
FT                   /evidence="ECO:0000269|PubMed:19039103,
FT                   ECO:0000269|PubMed:19948726"
FT   MUTAGEN         37
FT                   /note="F->A: Strongly reduced interaction with PLCB2."
FT                   /evidence="ECO:0000269|PubMed:17115053"
FT   MUTAGEN         56
FT                   /note="W->A: Strongly reduced interaction with PLCB2."
FT                   /evidence="ECO:0000269|PubMed:17115053"
FT   MUTAGEN         61
FT                   /note="Q->L: Constitutively active. Interacts with PARD6
FT                   proteins. Interacts with PPP5C, activates its phosphatase
FT                   activity and translocates PPP5C to the plasma membrane. No
FT                   effect on interaction with RAPH1. Interacts with CYRIB. No
FT                   interaction with PPP5C; when associated with V-30 or S-35.
FT                   Translocates to the plasma membrane; also when associated
FT                   with V-30 or S-35."
FT                   /evidence="ECO:0000269|PubMed:10954424,
FT                   ECO:0000269|PubMed:18499456, ECO:0000269|PubMed:19948726,
FT                   ECO:0000269|PubMed:29074776, ECO:0000269|PubMed:30250061,
FT                   ECO:0000269|PubMed:38332367"
FT   MUTAGEN         67
FT                   /note="L->A: Strongly reduced interaction with PLCB2."
FT                   /evidence="ECO:0000269|PubMed:17115053"
FT   MUTAGEN         70
FT                   /note="L->A: Strongly reduced interaction with PLCB2."
FT                   /evidence="ECO:0000269|PubMed:17115053"
FT   MUTAGEN         71
FT                   /note="S->A: Loss of AKT-mediated phosphorylation and
FT                   FBXL19-induced polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:10617634,
FT                   ECO:0000269|PubMed:23512198"
FT   MUTAGEN         166
FT                   /note="K->R: Loss of FBXL19-induced polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:23512198"
FT   MUTAGEN         183..188
FT                   /note="KKRKRK->AARARA: In 4KA mutant; abolished
FT                   palmitoylation by the V.cholerae toxin RtxA."
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   MUTAGEN         183
FT                   /note="K->A: Slightly decreased palmitoylation by the
FT                   V.cholerae toxin RtxA."
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   MUTAGEN         184
FT                   /note="K->A: Slightly decreased palmitoylation by the
FT                   V.cholerae toxin RtxA."
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   MUTAGEN         185..187
FT                   /note="RKR->AKA: In 2RA mutant; does not affect
FT                   palmitoylation by the V.cholerae toxin RtxA."
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   MUTAGEN         186
FT                   /note="K->A: Decreased palmitoylation by the V.cholerae
FT                   toxin RtxA."
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   MUTAGEN         188
FT                   /note="K->A: Decreased palmitoylation by the V.cholerae
FT                   toxin RtxA."
FT                   /evidence="ECO:0000269|PubMed:29074776"
FT   CONFLICT        192
FT                   /note="Missing (in Ref. 2; AAA36544)"
FT                   /evidence="ECO:0000305"
FT   STRAND          2..9
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           12..14
FT                   /evidence="ECO:0007829|PDB:6X1G"
FT   HELIX           16..25
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           29..31
FT                   /evidence="ECO:0007829|PDB:8I5V"
FT   STRAND          39..46
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   STRAND          49..56
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   TURN            65..67
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           68..71
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:7USE"
FT   STRAND          76..83
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           87..95
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           97..104
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   STRAND          106..108
FT                   /evidence="ECO:0007829|PDB:6X1G"
FT   STRAND          110..115
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           117..120
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           123..131
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           139..148
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   STRAND          152..156
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   TURN            159..161
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   HELIX           165..176
FT                   /evidence="ECO:0007829|PDB:1MH1"
FT   MOD_RES         P63000-2:71
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
SQ   SEQUENCE   192 AA;  21450 MW;  ACEDF83A45E5EA67 CRC64;
     MQAIKCVVVG DGAVGKTCLL ISYTTNAFPG EYIPTVFDNY SANVMVDGKP VNLGLWDTAG
     QEDYDRLRPL SYPQTDVFLI CFSLVSPASF ENVRAKWYPE VRHHCPNTPI ILVGTKLDLR
     DDKDTIEKLK EKKLTPITYP QGLAMAKEIG AVKYLECSAL TQRGLKTVFD EAIRAVLCPP
     PVKKRKRKCL LL
//